[HTML][HTML] Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey
Abstract Background The Philadelphia chromosome− negative myeloproliferative
neoplasms (MPN) myelofibrosis (MF), polycythemia vera (PV), and essential …
neoplasms (MPN) myelofibrosis (MF), polycythemia vera (PV), and essential …
[HTML][HTML] Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
JC Bryan, S Verstovsek - Cancer chemotherapy and pharmacology, 2016 - Springer
Myelofibrosis (MF) and polycythemia vera (PV) are BCR-ABL1-negative myeloproliferative
neoplasms associated with somatic hematopoietic stem cell mutations leading to over …
neoplasms associated with somatic hematopoietic stem cell mutations leading to over …
[HTML][HTML] The use of anagrelide in myeloproliferative neoplasms, with focus on essential thrombocythemia
G Birgegård - Current Hematologic Malignancy Reports, 2016 - Springer
Anagrelide (ANA) is a drug with specific platelet-lowering activity, used primarily in ET,
registered as a second-line drug in essential thrombocythemia (ET) in Europe and in some …
registered as a second-line drug in essential thrombocythemia (ET) in Europe and in some …
Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease
H Geyer, R Scherber, H Kosiorek, AC Dueck… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with
disabling symptoms and a heightened risk of life-threatening complications. Recent studies …
disabling symptoms and a heightened risk of life-threatening complications. Recent studies …
Comprehensively understanding fatigue in patients with myeloproliferative neoplasms
RM Scherber, HE Kosiorek, Z Senyak, AC Dueck… - Cancer, 2016 - Wiley Online Library
BACKGROUND Patients with myeloproliferative neoplasms (MPNs) experience a high
persistence, prevalence, and severity of fatigue. There is currently only limited information …
persistence, prevalence, and severity of fatigue. There is currently only limited information …
Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group
of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia …
of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia …
Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
R Mesa, S Verstovsek, JJ Kiladjian… - European journal of …, 2016 - Wiley Online Library
Objectives Polycythemia vera (PV)‐related symptoms may not be adequately controlled with
conventional therapy. This current analysis of the RESPONSE trial evaluated the effects of …
conventional therapy. This current analysis of the RESPONSE trial evaluated the effects of …
[HTML][HTML] 615 例Ph 染色体/BCR-ABL 融合基因阴性骨髓增殖性肿瘤患者的症状负荷评估
徐俊卿， 徐泽锋， 王静雅， 李冰， 孙秀娟… - Chinese Journal of …, 2016 - ncbi.nlm.nih.gov
615例PH染色体/BCR-ABL融合基因阴性骨髓增殖性肿瘤患者的症状负荷评估- PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group
HL Geyer, B Andreasson, HE Kosiorek, AC Dueck… - Cancer, 2016 - Wiley Online Library
BACKGROUND Patients with myeloproliferative neoplasms (MPNs) including polycythemia
vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom …
vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom …
Individualizing care for patients with myeloproliferative neoplasms: integrating genetics, evolving therapies, and patient-specific disease burden
RA Mesa, F Passamonti - American Society of Clinical Oncology …, 2016 - ascopubs.org
Individualized medicine is important for patients with myeloproliferative neoplasms (MPNs),
including essential thrombocythemia, polycythemia vera, and myelofibrosis, which are …
including essential thrombocythemia, polycythemia vera, and myelofibrosis, which are …